Not Yet Recruiting
Study to Evaluate the Efficacy and Safety of Axicabtagene Ciloleucel Injection as First-Line Therapy of High-Risk Large B-Cell Lymphoma
NCT06935136
- Conditions
- CAR-T Cell Therapy, High-risk Large B-cell Lymphoma (LBCL)
- Locations
-
- China Shanghai, Shanghai Municipality, China